Comparison of Human Mesenchymal Stem Cells Derived from Bone Marrow and Adipose Tissue and Decidua

Subject Areas :

Sepideh Kazemi ¹ ( PhD student in Animal Science, Cell-Tachin Development, Department of Animal Biology, Islamic Azad University, Science and Research Branch, Tehran, Iran. )
kazm parivar ² ( واحد علوم وتحقیقات دانشگاه آزاد )
نسیم حیاتی رودباری ³ ( دانشگاه آزاد اسلامی واحد علوم و تحقیقات )
پریچهر یغمایی ⁴ ( علوم و تحقیقات )
بهنام صادقی ⁵ ( )

Received: 2019-12-25 Accepted : 2020-05-11 Published : 2020-06-21

Keywords: Freshwater Gammarus (Gammarus fasciatus), DO2, Lakanshahr altitude, Temp,

Abstract :

Inroduction & Objective: Stem cell therapy has introduced a new approach to repair and regeneration of organs and tissues. Mesenchymal stem cells (MSCs) are promising candidates for cell therapy. Although bone marrow-derived MSCs are able to differentiate into several cell lines, bone marrow is not an appropriate cell source due to the problem of cell division and low efficiency. The aim of this study was to compare the healing potential of human MSCs obtained from three sources including Bone marrow (BM-MSCs) and adipose tissue (AT-MSCs) and fetal membrane decidua (DSCs) tissue in vitro.  Material and Methods: MSCs were isolated from the human Bone marrow, Adipose tissue and decidua stromal cell , cultured for 10 passages, and assessed for: phenotype with immunofluorescence and flow cytometry, multipotency with differentiation capacity for osteo-, chondro-, and adipogenesis, growth evaluation with population doubling time and population doubling level was performed. Results: Despite of similarities in terms of surface antigen expression and self-renewal capacity, MSCs of different sources demonstrated significant differences with regards to proliferation and multi-lineage differentiation capacities. DSCs showed the highest cell proliferation capacity and appeared to preserve it up to the tenth passage whereas BM-MSCs possessed significant advantage for osteogenic and chondrogenic differentiation and AT-MSCs showed the most potent adipogenic differentiation capacity among the others. Although demonstrating significant advantage for cell proliferation capacity, DSCs possessed the lowest osteogenic, chondrogenic and adipogenic differentiation capacities. Conclusion: Because AT-MSCs and DSCs as effectively as BM-MSCs, AT-MSCs and DSCs may constitute an alternative source for BM-MSCs.

References:

 

1.Alabdulkarim, Y., Ghalimah, B., Al-Otaibi, M., Al-Jallad, H.F., Mekhael, M., Willie, B. (2017). Recent advances in bone regeneration: The role of adipose tissue-derived stromal vascular fraction and mesenchymal stem cells. Journal of Limb Lengthening & Reconstruction, 3(1) 4.

2.Araújo, A.B., Salton, G.D., Furlan, J.M., Schneider, N., Angeli, M.H., Laureano, Á.M. (2017). Comparison of human mesenchymal stromal cells from four neonatal tissues: amniotic membrane, chorionic membrane, placental decidua and umbilical cord. Cytotherapy, 19(5); 577-585.

3.Casado‐Díaz, A., Anter, J., Müller, S., Winter, P., Quesada‐Gómez, J.M., Dorado, G. (2017). Transcriptomic analyses of adipocyte differentiation from human mesenchymal stromal‐cells (MSC). Journal of Cellular Physiology, 232(4); 771-784.

4.Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society For Cellular Therapy Position Statement, Cytotherapy, 8(4); 315-317.

5.Galleu, A. , Riffo-Vasquez, Y., Trento, C., Lomas, C., Dolcetti, L., Cheung, T.S. (2017). Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Science Translational Medicine, 9(416); eaam7828.

6.Jin, H.J., Bae, Y.K., Kim, M., Kwon, S.-J., Jeon, H.B., Choi, S.J. (2013). Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy, International Journal of Molecular Sciences, 14(9); 17986-18001.

7.Li, H., Ghazanfari, R., Zacharaki, D., Lim, H.C., Scheding, S. (2016). Isolation and characterization of primary bone marrow mesenchymal stromal cells. Annals of the New York Academy of Sciences, 1370(1); 109-118.

8.Moll, G., Ankrum, J.A., Kamhieh-Milz, J., Bieback, K., Ringdén, O., Volk, H.-D. (2019). Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines, Trends in Molecular Medicine .

9.Pereira, M.R.d.J., Pinhatti, V.R., Silveira, M.D.d., Matzenbacher, C.A., Freitas, T.R.O.d., Silva, J.d. (2018). Isolation and characterization of mesenchymal stem/stromal cells from Ctenomys minutus. Genetics and Molecular Biology, 41(4); 870-877.

10.Pfeiffer, D., Wankhammer, K., Stefanitsch, C., Hingerl, K., Huppertz, B., Dohr, G. (2019). Lang, amnion-derived mesenchymal stem cells improve viability of endothelial cells exposed to shear stress in eptfe grafts. The International Journal of Artificial Organs, 42(2); 80-87.

11.Rizzuto, G.A., M. Kapidzic, M. Gormley, A.I. Bakardjiev, Human Placental and Decidual Organ Cultures to Study Infections at the Maternal-fetal Interface, JoVE (Journal of Visualized Experiments) (113) (2016) e54237-e54237.

12.Romanov, Y.A., Darevskaya, A., Merzlikina, N., Buravkova, L. (2005). Mesenchymal stem cells from human bone marrow and adipose tissue: isolation, characterization, and differentiation potentialities. Bulletin of Experimental Biology and Medicine, 140(1); 138-143.

13.Sharma, R.R., Pollock, K., Hubel, A., McKenna, D. (2014). Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion, 54(5); 1418-1437.

14.Shi, Y.-Y., Nacamuli, R.P., Salim, A., Longaker, M.T. (2005). The osteogenic potential of adipose-derived mesenchymal cells is maintained with aging. Plastic and Reconstructive Surgery, 116(6); 1686-1696.

15.Schipper, B.M., Marra, K.G., Zhang, W., Donnenberg, A.D., Rubin, J.P. (2008). Regional anatomic and age effects on cell function of human adipose-derived stem cells. Annals of Plastic Surgery, 60(5); 538-544.

16.Squillaro, T., Peluso, G., Galderisi, U. (2016). Clinical trials with mesenchymal stem cells: an update, Cell Transplantation, 25(5); 829-848.

17.Wakitani, S., Saito, T., Caplan, A.I. (1995). Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5‐azacytidine, Muscle & Nerve, 18(12); 1417-1426.

18.Wilson, A., Chee, M., Butler, P., Boyd, A.S. ( 2019). Isolation and characterisation of human adipose-derived stem cells. Immunological Tolerance, Springer, pp; 3-13.